MYRIAD GENETICS DL-,01 | 17,820 / +2,65% |
Data / Laikas | 01.07. / 21:43 |
Pok. / Pok.(%) | 0,460 / +2,65% |
Bid | 17,830 / 280 |
Ask | 17,905 / 280 |
Atidaryti | 17,290 |
Ankstesnį uždaryti | 17,360 |
Aukšč. | 17,820 |
Žem. | 17,290 |
APYVARTA [EUR] | - |
APYVARTA [Units] | |
Price fixings | 9 |
ISIN | US62855J1043 |
Simbolis | MYD |
Birža | gettex |
Rūšis | Stock |
Visos biržos
Birža | Paskutinis | APYVARTA | |
---|---|---|---|
Lang & Schwa.. | 17,690 | ![]() |
|
NASDAQ | 18,6300 | ![]() |
439.907 |
IEX | 18,60 | ![]() |
22.765 |
Cboe US | 18,60 | ![]() |
9.352 |
Xetra | 17,760 | ![]() |
0 |
Hannover | 17,160 | ![]() |
0 |
Frankfurt | 17,1150 | ![]() |
0 |
Berlin | 17,120 | ![]() |
0 |
München | 17,275 | ![]() |
0 |
Hamburg | 17,160 | ![]() |
0 |
Düsseldorf | 17,580 | ![]() |
0 |
Stuttgart | 17,105 | ![]() |
0 |
gettex | 17,820 | ![]() |
|
Quotrix | 17,2150 | ![]() |
|
London Domes.. | 19,45 | 31 | |
TradeGate | 16,450 | 600 |
Naujienos
- Myriad Genetics Advances Precision Oncology with New Precise™ Solutions, Combines Genetic Insights from Multiple Tests to Guide Treatment Decisions and Improve Patient Care
14.03.2022 / 12:05 - GlobeNewswire - Myriad Genetics Receives FDA Approval of BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Early Breast Cancer
12.03.2022 / 01:05 - GlobeNewswire - Myriad Genetics Named to Fast Company’s Annual List of World’s Most Innovative Companies
08.03.2022 / 13:22 - GlobeNewswire - Myriad Genetics CEO Paul Diaz to Speak at 42nd Annual Cowen Health Care Conference
02.03.2022 / 22:30 - GlobeNewswire - Myriad Genetics Reports Fourth Quarter 2021 Results, Provides Updates on Product Performance and Growth Initiatives
24.02.2022 / 15:00 - GlobeNewswire
Click on
to activate push quotes.
